IDEXX LABORATORIES INC /DE — Director's Dealing 2016

Feb 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2016-02-05

Reporting Person: MCKEON BRIAN P (EVP, CFO and Treasurer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-05	Common Stock	M	1880	$53.185	Acquired	32461	Direct
2016-02-08	Common Stock	M	9054	$17.185	Acquired	41515	Direct
2016-02-08	Common Stock	S	4200	$69.1683	Disposed	37315	Direct
2016-02-08	Common Stock	S	4854	$70.0619	Disposed	32461	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-05	Incentive Stock Option (right-to-buy)	$53.185	M	1880	Disposed	2023-12-31	Common Stock (1880)	Direct
2016-02-08	Non-Qualified Stock Option (right-to-buy)	$17.185	M	9054	Disposed	2016-02-13	Common Stock (9054)	Direct

Footnotes

F1: The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").

F2: Sale made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $68.73 to a high of $69.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $69.76 to a high of $70.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: This option vests in five equal annual installments, beginning on the first anniversary date (01/01/2015) of the date of grant. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Not applicable.